1. , , , et al. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 1986; 43:341–6.
2. . Reproductive dysfunction in women with epilepsy. Neurology 2003; 61(6 Suppl 2):S27–S34.
3. , and . Ovulatory function in epilepsy. Epilepsia 1995; 36:355–60.
4. , and . Marriage and fertility in epileptic patients. Epilepsia 1980; 21:261–71.
5. , and . Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet 1998; 352:1970–73.
6. , , , et al. Birth rate among patients with epilepsy: a nationwide population-based cohort study in Finland. Am J Epidemiol 2004; 159:1057–63.
7. , and . Polytherapy increases the risk of infertility in women with epilepsy. Neurology 2010; 75(15):1351–5.
8. , , , et al. Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia 1995; 36:676–81.
9. , , , et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. New Engl J Med 1993; 329(19):1383–9.
10. , , , et al. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol 1998; 43:446–51.
11. , , , et al. Long-term reproductive endocrine health in young women with epilepsy during puberty. Neurology 2004; 62:445–50.
12. . Disorders of reproduction in patients with epilepsy: antiepileptic drug related mechanisms. Seizure 2008; 17:111–19.
13. , , , et al. Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 2011; 52:199–211.
14. , , , et al. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res 2000; 41:163–7.
15. , and . Ovarian hypertension: polycystic ovary syndrome. Endocrinol Metab Clin North Am 2011; 40:433–8.
16. , , , at al. Interictal EEG discharges, reproductive hormones, and menstrual disorders in epilepsy. Ann Neurol 2003; 54:625–37.
17. . Disorders of reproduction in patients with epilepsy: primary neurological mechanisms. Seizure 2008; 17:101–10.
18. , , , at al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005; 7:246–59.
19. , , , at al. Seizure type, antiepileptic drugs, and reproductive endocrine dysfunction in Indian women with epilepsy: a cross-sectional study. Epilepsia 2008; 49:2069–77.
20. , , , at al. Hyperandrogenism, ovulatory dysfunction, polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol 2008; 64:200–11.
21. , and . Clinical gynecologic endocrinology and infertility. 7th edn. Philadelphia, IL: Lippincott Williams & Wilkins, 2004.
22. , , , at al. Valproate inhibits the conversion of testosterone to estradiol and acts as an apoptotic agent in growing porcine ovarian follicular cells. Epilepsia 2003; 44:1014–21.
23. , , , at al. Valproate potentiates androgen biosynthesis in human ovarian theca cells. Endocrinology 2004; 145:799–808.
24. , , , at al. Differential effects of levetiracetam, carbamazepine, and lamotrigine on reproductive endocrine function in adults. Epilepsy Behav 2009; 16:281–7.
25. and . Amenorrhea following initiation of therapy with valproic acid. Neurology 1981; 31(Suppl):S159.
26. , and . Premature ovarian failure in women with epilepsy. Epilepsia 2001; 42:1584–9.
27. and . Self-reported sexual function and sexual arousability in women with epilepsy. Epilepsia 1996; 37:1204–10.
28. , , , et al. Sexual dysfunction, sex steroid hormone abnormalities, and depression in women with epilepsy treated with antiepileptic drugs. Epilepsy Behav 2005; 6:360–5.
29. , , , at al. Relationship of sexual dysfunction to epilepsy laterality and reproductive hormone levels in women. Epilepsy Behav 2003; 4:407–13.
30. , , , at al. Reproductive dysfunction in women with epilepsy: antiepileptic drug effects on sex-steroid hormones. CNS Spectr 2001; 6:783–6.
31. , , , at al. Changes in sex steroid levels in women with epilepsy on treatment: relationship with antiepileptic therapies and seizure frequency. Epilepsia 2009; 50:(Suppl 1):28–32.
32. , , , et al. Reversible effects of antiepileptic drugs on reproductive endocrine function in men and women with epilepsy – a prospective randomized double-blind withdrawal study. Epilepsia 2007; 48:1875–82.
33. . Sexuality in women with epilepsy. Epilepsy Behav 2005; 7(Suppl 2):S2–S6.
34. . Weight issues for people with epilepsy – a review. Epilepsia 2007; 48(Suppl 9):42–5.
35. , , , at al. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev 2011; 12:e32–43.
36. , , , et al. Valproate, weight gain and carbohydrate craving: a gender study. Seizure 2007; 16:226–32.
37. , and . Metabolic alterations during valproic acid treatment: a prospective study. Pediatr Neurol 2009; 41:435–9
38. , , , et al. Plasma leptin, neuropeptide Y, ghrelin, and adiponectin levels and carotid artery intima media thickness in epileptic children treated with valproate. Childs Nerv Syst 2012; 28:1049–53.
39. , , , et al. The role of valproate in metabolic disturbances in bipolar disorder patients. J Affect Disord 2010; 124:319–23.
40. , , , et al. The metabolic syndrome in overweight epileptic patients treated with valproic acid. Epilepsia 2010; 51:268–73.
41. and . Acute pancreatitis and diabetic ketoacidosis in non-diabetic person while on treatment with sodium valproate, chlorpromazine and haloperidol. J Assoc Physicians India 2004; 52:257–8.
42. and . Can diabetes mellitus be induced by medication? J Child Adolesc Psychopharmacol 2002; 12:231–6.
43. , , , et al. Serum insulin and leptin levels in valproate-associated obesity. Epilepsia 2002; 43:514–7.
44. , , , et al. Characterization of insulin secretion in valproate-treated patients with epilepsy. Epilepsia 2006; 47:1460–4.
45. . Optimizing therapy of seizures in patients with endocrine disorders. Neurology 2006; 67(Suppl 4):S23–S7.
46. , , , et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin 2012; 28:1027–37.
47. , , , et al. Long-term add-on pregabalin treatment in patients with partial-onset epilepsy: pooled analysis of open-label clinical trials. Epilepsia 2010; 51:968–78.
48. and . Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. The Canadian Vigabatrin Study Group. Seizure 2000; 9:112–8.
49. , , , et al. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003; 11:556–62
50. , , , et al. Investigators randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurol Scand 2005; 112:214–22.
51. , , , et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring) 2012; 20:330–42.
52. , , , et al. Topiramate treatment improves hypothalamic insulin and leptin signaling and action and reduces obesity in mice. Endocrinology 2012; 153:4401–11.
53. , , , et al. Topiramate and type 2 diabetes: an old wine in a new bottle. Expert Opin Ther Targets 2008; 12:81–90.
54. . Effects of topiramate on diabetes mellitus induced by streptozotocin in rats. Eur J Pharmacol 2012; 684:161–7.
55. , , , et al. OBDM-OBDM-003 Study Group. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab 2007; 9:360–8.
56. , , , et al. OBD-202 Study Group. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. Diabetes Care 2007; 30:1480–6.
57. , , , et al. Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001; 57:1774–9.
58. , , , et al. Zonisamide for weight reduction in obese adults: a 1-year randomized controlled trial. Arch Intern Med 2012; 15:1–8.
59. . Hormonal aspects of epilepsy. Neurol Clin 2009; 27:941–65.
60. , , , et al. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia 2004; 45:197–203.
61. , , , et al. Thyroid hormones in children with epilepsy during long-term administration of carbamazepine and valproate. Eur J Endocrinol 2009; 160:81–6.
62. , , , et al. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005; 27:1976–8.
63. , , , et al. Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy. Clin Neuropharmacol 2010; 33:293–6.
64. , , , et al. The regulation of serum sodium after replacing carbamazepine with oxcarbazepine. Epilepsia 2001; 42:741–5.
65. , , , et al. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatraemia associated with valproic acid: four case reports from the Netherlands and a case/non-case analysis of vigibase. Drug Saf 2010; 33:47–55.
66. and . Hyponatremia associated with repeated use of levetiracetam. Epilepsia 2005; 46:972–3.